CFA
NBIX icon

Carroll Financial Associates’s Neurocrine Biosciences NBIX Stock Holding History

Carroll Financial Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18
Closed -$2K – 1607
2020
Q2 		$2K Sell
18
-200
-92% -$22.1K ﹤0.01% 1364
2020
Q1 		$18K Buy
218
+200
+1,111% +$19.6K ﹤0.01% 805
2019
Q4 		$1K Hold
18
– – ﹤0.01% 1458
2019
Q3 		$1K Hold
18
– – ﹤0.01% 1432
2019
Q2 		$1K Buy
+18
New +$1.48K ﹤0.01% 1483

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carroll Financial Associates's NBIX Position: Q3 2020 in Review

Carroll Financial Associates sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 18 shares — an estimated $2K sold.

Carroll Financial Associates first reported a position in NBIX in Q2 2019 and held it in 5 quarters. The position peaked at $18K in Q1 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Carroll Financial Associates reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Carroll Financial Associates sold 18 Neurocrine Biosciences shares in Q3 2020, an estimated $2K.
  • Carroll Financial Associates first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 5 quarters.
  • Carroll Financial Associates's Neurocrine Biosciences position peaked at $18K in Q1 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Carroll Financial Associates's 13F filing for Q3 2020, filed 6 Oct 2020.